Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Merker

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Diabetic Medicine : a Journal of the British Diabetic Association|May 29, 2013
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trialB W Bode, J B Buse, M Fisher, et al.
Clinical Biochemistry|December 25, 2012
Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosisMiriam J Smith, Sonia Esparza, Vanessa L Merker, et al.
Familial Cancer|December 16, 2025
"It's not any one thing, it's always all of them, all at the same time": quality of life in NF2-related schwannomatosis from patient and clinician perspectivesSophia C Carias, Frank D Buono, Liesel Von Imhof, et al.
Contemporary Clinical Trials|August 29, 2022
Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related painJennifer L W Da, Vanessa L Merker, Justin T Jordan, et al.
Clinical Trials (London, England)|November 14, 2023
Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online surveyPamela L Wolters, Nour Al Ghriwati, Melissa Baker, et al.
Social Science & Medicine (1982)|July 16, 2021
"Because the country, it seems though, has turned their back on me": Experiences of institutional betrayal among veterans living with Gulf War IllnessKatharine Bloeser, Kelly K McCarron, Vanessa L Merker, et al.
Plos One|May 5, 2012
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosisScott R Plotkin, Miriam A Bredella, Wenli Cai, et al.
Developmental Medicine and Child Neurology|December 5, 2012
Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approachAgnies M van Eeghen, Margaret B Pulsifer, Vanessa L Merker, et al.
JAMA Network Open|October 17, 2025
Coherence of Stroke Survivors' Lived Experiences and the Stroke-Specific Quality of Life ScaleDevanshi Choksi, Mary Craven, Taylor McVeigh, et al.
American Journal of Medical Genetics. Part A|September 18, 2021
Impact of the coronavirus pandemic on mental health and health care in adults with neurofibromatosis: Patient perspectives from an online surveyPamela L Wolters, Stephanie Reda, Staci Martin, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Diabetic Medicine : a Journal of the British Diabetic Association|May 29, 2013
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trialB W Bode, J B Buse, M Fisher, et al.
Clinical Biochemistry|December 25, 2012
Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosisMiriam J Smith, Sonia Esparza, Vanessa L Merker, et al.
Familial Cancer|December 16, 2025
"It's not any one thing, it's always all of them, all at the same time": quality of life in NF2-related schwannomatosis from patient and clinician perspectivesSophia C Carias, Frank D Buono, Liesel Von Imhof, et al.
Contemporary Clinical Trials|August 29, 2022
Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related painJennifer L W Da, Vanessa L Merker, Justin T Jordan, et al.
Clinical Trials (London, England)|November 14, 2023
Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online surveyPamela L Wolters, Nour Al Ghriwati, Melissa Baker, et al.
Social Science & Medicine (1982)|July 16, 2021
"Because the country, it seems though, has turned their back on me": Experiences of institutional betrayal among veterans living with Gulf War IllnessKatharine Bloeser, Kelly K McCarron, Vanessa L Merker, et al.
Plos One|May 5, 2012
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosisScott R Plotkin, Miriam A Bredella, Wenli Cai, et al.
Developmental Medicine and Child Neurology|December 5, 2012
Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approachAgnies M van Eeghen, Margaret B Pulsifer, Vanessa L Merker, et al.
JAMA Network Open|October 17, 2025
Coherence of Stroke Survivors' Lived Experiences and the Stroke-Specific Quality of Life ScaleDevanshi Choksi, Mary Craven, Taylor McVeigh, et al.
American Journal of Medical Genetics. Part A|September 18, 2021
Impact of the coronavirus pandemic on mental health and health care in adults with neurofibromatosis: Patient perspectives from an online surveyPamela L Wolters, Stephanie Reda, Staci Martin, et al.
Pageof 8